# DeLorean Artificial Intelligence

> DeLorean Artificial Intelligence is a Palm Beach, Florida-based healthcare AI company that builds predictive and interventive intelligence to forecast chronic disease and recommend next-best clinical actions before a patient gets sicker. Its flagship Medical AI platform, MARTI, analyzes structured and unstructured health records to predict events like hospitalizations and disease progression - and is described as the first medical AI to be biologically validated by independent third parties. Founded in 2019 by Dr. Severence MacLaughlin, the company also applies its predictive engine to sales/CRM, life sciences, financial services and other industries.

- **Founded:** 2019
- **Headquarters:** Palm Beach, Florida, United States
- **Founders:** Dr. Severence MacLaughlin (Founder & CEO)
- **Team size:** ~25 employees (grew roughly 50% after the 2023 Series A)
- **Products:** Medical AI (MARTI), Real Time Medical Care Management AI (RTMCM AI), Disease-Specific Care Modules, CRM AI (Sales Intelligence)
- **Notable:** Described as the first medical AI to be biologically validated by a third-party review, Reported 85-87% accuracy on disease prediction using electronic medical, healthcare and hospitalization records, 27% reduction in adverse outcomes within the first 90 days at hospitals using the system

## Products & services

- **Medical AI (MARTI)** — Flagship healthcare platform that creates mathematical profiles of patient journeys to predict future health events and deliver next-best-action recommendations. Described as the first medical AI to be biologically validated by independent third parties, with predictions reported accurate at a 95-99% confidence level.
- **Real Time Medical Care Management AI (RTMCM AI)** — Analyzes patient data to provide real-time risk predictions and interventive next-best actions for care managers across disease modules including end-stage renal failure, cardiovascular disease, COPD, diabetes and juvenile asthma.
- **Disease-Specific Care Modules** — Predictive modules spanning chronic kidney disease, diabetes, cardiovascular disease, behavioral health/depression and respiratory disease (COPD), including identification of undiagnosed patients and disease-progression tracking.
- **CRM AI (Sales Intelligence)** — Patent-pending system that predicts whether a deal will close, where in the sales cycle it may die, and recommends next best actions. Integrates with any CRM and has delivered roughly a 7% sales increase for clients.

## Achievements

- Described as the first medical AI to be biologically validated by a third-party review
- Reported 85-87% accuracy on disease prediction using electronic medical, healthcare and hospitalization records
- 27% reduction in adverse outcomes within the first 90 days at hospitals using the system
- Analyzed 80+ million patient records; 7 patents backing the technology
- Reported $100 PMPM ($1,200 annualized) savings on the sickest 1% of members and ~$10 PMPM on the remaining 99%
- Raised $7.55M Series A in September 2023, bringing total funding to roughly $11M

## Latest updates

- **2023-09** — Closed $7.55M Series A led by Sopris Venture Capital, with Pinta Capital Partners and James Chow participating; planned ~50% team expansion.
- **2024-01** — Refreshed brand and Medical AI / MARTI positioning across renal, diabetes, cardiovascular, behavioral and respiratory modules.

## Links

- Website: https://deloreanai.com
- LinkedIn: http://www.linkedin.com/company/delorean-artificial-intelligence
- Twitter/X: https://twitter.com/deloreanai/
- YouTube: https://www.youtube.com/watch?v=RyTxz45PpqY
- Instagram: https://www.instagram.com/deloreanai/

---

Profile page: https://yespress.io/delorean-artificial-intelligence
Published by YesPress — https://yespress.io
Last updated: 2026-06-15